Recently published papers: Sepsis--guidelines, treatment and novel approaches.
The choice of inotropic agent, particularly in catecholamine-resistant septic shock, remains an area of debate. Here we discuss a recent trial examining the use of vasopressin in a carefully controlled trial setting. Yet more data on the use of drotrecogin alfa (activated) in septic shock are described, as are novel but as yet experimental approaches to the treatment of sepsis. Finally, it is important not to forget to read the latest surviving sepsis guidelines.
Kalsi
Navneet
N
Department of Critical Care, Worthing General Hospital, Lyndhurst Road, Worthing, West Sussex BN11 2DH, UK.
Forni
Lui G
LG
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015994:Incidence; D009638:Norepinephrine / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012772:Shock, Septic / Q000188:drug therapy* / Q000208:ethnology / Q000401:mortality / Q000503:physiopathology; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014667:Vasopressins / Q000627:therapeutic use
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; D014667:Vasopressins; C421124:drotrecogin alfa activated; D009638:Norepinephrine